New Lyme disease vaccine shows over 70% efficacy

A candidate vaccine developed by Pfizer and Valneva has demonstrated more than 70% efficacy in a Phase III clinical trial in individuals aged five years and older. The results represent a significant step towards the prevention of this tick-borne disease, although the study did not meet one of its primary statistical endpoints due to fewer-than-expected cases during the trial. 

More information in the article: www.euronews.com - By Marta Iraola Iribarren, Published on 23/03/2026